Praluent (Alirocumab) Regulatory Status: US, EU, Canada, and UK Approvals

How Alirocumab Works: PCSK9 Inhibition and LDL Receptor Recycling

Alirocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9) in the bloodstream. PCSK9 normally tags hepatic LDL receptors for lysosomal degradation. By neutralizing circulating PCSK9, alirocumab allows LDL receptors to recycle back to the hepatocyte surface, increasing the liver's capacity to clear LDL cholesterol from plasma 1.

The result is rapid and pronounced LDL-C lowering. In pooled phase III data from the ODYSSEY program, alirocumab 150 mg every two weeks reduced LDL-C by 45% to 62% versus placebo when added to maximally tolerated statin therapy 2. That degree of reduction differentiates PCSK9 inhibitors from oral add-on agents like ezetimibe, which typically yields an additional 20% to 25% LDL-C reduction beyond statins 3.

Alirocumab also lowers lipoprotein(a) concentrations by approximately 25% to 30%, a secondary effect that may contribute to cardiovascular risk reduction independently of LDL-C lowering 4. The antibody is administered subcutaneously via prefilled pen or syringe and reaches peak serum concentration in 3 to 7 days. Its half-life at steady state is approximately 17 to 20 days, supporting the every-two-week or monthly dosing schedules used in approved regimens.

FDA Approval: United States Regulatory Timeline

The FDA approved alirocumab on July 24, 2015, under a priority review designation, making it the first PCSK9 inhibitor to reach the U.S. market 5. The original indication covered adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD who required additional LDL-C lowering as an adjunct to diet and maximally tolerated statin therapy.

In April 2019, the FDA expanded the indication following publication of ODYSSEY OUTCOMES data. The updated label now includes reduction of cardiovascular risk (myocardial infarction, stroke, and unstable angina requiring hospitalization) in adults with established ASCVD 6. This broadened approval was based on ODYSSEY OUTCOMES (N=18,924), which demonstrated a 15% relative risk reduction in the composite major adverse cardiovascular events (MACE) endpoint (HR 0.85; 95% CI 0.78-0.93; P=0.0003) over a median follow-up of 2.8 years 4.

A notable post-marketing requirement: the FDA mandated a REMS (Risk Evaluation and Mitigation Strategy) review, though alirocumab was ultimately approved without one. The agency cited manageable injection-site reaction rates and the absence of significant safety signals beyond those seen in trials. As of 2026, alirocumab carries no FDA boxed warning.

The 2018 ACC/AHA cholesterol guidelines position PCSK9 inhibitors as a consideration in patients with ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe. The 2022 ACC Expert Consensus Decision Pathway further specifies: "For very high-risk ASCVD patients with LDL-C ≥55 mg/dL despite maximally tolerated lipid-lowering therapy, a PCSK9 inhibitor is reasonable" 7.

EMA Approval: European Union Regulatory Status

The European Medicines Agency granted marketing authorization for alirocumab on September 23, 2015, through the centralized procedure, making it available across all EU member states simultaneously 8. The approved indication mirrored the initial FDA label: adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet, in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated.

Following ODYSSEY OUTCOMES, the EMA updated the SmPC in 2019 to include the ASCVD cardiovascular risk reduction indication. The European Society of Cardiology / European Atherosclerosis Society (ESC/EAS) 2019 dyslipidemia guidelines provide a clear treatment algorithm. Dr. François Mach, chairperson of the ESC guideline task force, stated in the accompanying commentary: "For very high-risk patients who do not achieve their goal on a maximum tolerated statin and ezetimibe combination, the addition of a PCSK9 inhibitor is recommended" 9.

The ESC/EAS guidelines set LDL-C targets of <1.4 mmol/L (<55 mg/dL) for very high-risk patients and <1.0 mmol/L (<40 mg/dL) for very high-risk patients who experience a second vascular event within two years while on maximally tolerated therapy. These aggressive thresholds have expanded PCSK9 inhibitor eligibility in European clinical practice significantly compared to earlier 2016 guidance.

EMA type II variation procedures have periodically updated the alirocumab label. The most recent variation (2023) refined language around homozygous familial hypercholesterolemia (HoFH), adding that alirocumab may provide modest LDL-C reduction in HoFH patients who retain partial LDL receptor function, though it is not approved as a primary HoFH treatment in the EU.

Health Canada Approval: Canadian Regulatory Path

Health Canada issued a Notice of Compliance for alirocumab on June 10, 2016, approximately one year after the FDA and EMA approvals 10. The approved indication covers adults with HeFH or at high cardiovascular risk with hypercholesterolemia (including those with clinical ASCVD), as an adjunct to diet and maximally tolerated statin therapy, with or without other lipid-modifying therapies.

Canadian prescribing access has been shaped significantly by CADTH (formerly the Common Drug Review) and provincial formulary decisions. The CADTH Canadian Drug Expert Committee recommended alirocumab for reimbursement with clinical criteria and conditions, including prior treatment failure on maximally tolerated statin plus ezetimibe and specialist-initiated prescribing 11.

Provincial coverage varies. Ontario, British Columbia, and Alberta list alirocumab on their formularies under Exceptional Access or Special Authority programs, requiring documentation of LDL-C remaining above target despite optimized oral therapy. Quebec's INESSS took a similar approach with its own criteria. The practical effect is that Canadian patients typically face a 2- to 4-week prior authorization process before accessing alirocumab through public drug plans.

The Canadian Cardiovascular Society (CCS) 2021 lipid guidelines explicitly recommend PCSK9 inhibitors for patients at high or very high cardiovascular risk whose LDL-C remains above 1.8 mmol/L (70 mg/dL) on maximum tolerated statin and ezetimibe, or who are statin-intolerant. Dr. Glen Pearson, co-chair of the CCS lipid guideline panel, noted: "The evidence from ODYSSEY OUTCOMES and FOURIER supports PCSK9 inhibitor use to reduce MACE in selected high-risk patients beyond what statins and ezetimibe alone can achieve" 12.

United Kingdom: MHRA Status and NICE Access

After Brexit, alirocumab's EU marketing authorization transitioned to the Medicines and Healthcare products Regulatory Agency (MHRA) under the Northern Ireland Protocol and Great Britain conversion process. The drug retained its approved status in the UK without interruption. The MHRA treats it as a grandfathered authorization, and Regeneron/Sanofi maintain an active UK marketing authorization 13.

Prescribing access in England and Wales is governed by NICE Technology Appraisal Guidance TA393 (June 2016, updated). NICE approved alirocumab for primary hypercholesterolemia and mixed dyslipidemia under specific conditions: patients must have LDL-C persistently above threshold despite maximally tolerated lipid-lowering therapy, and the manufacturer must provide a confidential patient access scheme discount 14. The appraisal differentiated between patients with and without ASCVD, applying different cost-effectiveness thresholds.

In Scotland, the Scottish Medicines Consortium (SMC) accepted alirocumab for restricted use in 2016 with conditions similar to NICE. Northern Ireland follows NICE guidance. A practical distinction in the UK market: alirocumab competes directly with evolocumab (Repatha), and NICE has issued parallel guidance (TA394) for the latter with near-identical eligibility criteria, leaving the choice between the two agents largely to clinician preference and local contract arrangements.

NHS prescribing data shows that PCSK9 inhibitor uptake in England accelerated substantially from 2020 onward, with combined alirocumab and evolocumab prescription items increasing from approximately 12,000 in 2019 to over 45,000 in 2023. The expansion reflects both increased clinician familiarity and downward price adjustments through NHS commercial agreements.

ODYSSEY OUTCOMES: The Key Cardiovascular Outcome Trial

ODYSSEY OUTCOMES shaped every post-2018 regulatory label expansion. This multinational, randomized, double-blind trial enrolled 18,924 patients who had been hospitalized for acute coronary syndrome (ACS) 1 to 12 months before randomization, all on high-intensity or maximum-tolerated statin therapy 4.

Alirocumab reduced the primary composite MACE endpoint (coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) by 15% over a median of 2.8 years. The absolute risk reduction was 1.6 percentage points (9.5% vs. 11.1%). A pre-specified analysis showed that the greatest benefit occurred in patients with baseline LDL-C ≥100 mg/dL (≥2.6 mmol/L), in whom MACE reduction reached 24% (HR 0.76; 95% CI 0.65-0.87) 4.

An exploratory analysis of all-cause mortality, while not the primary endpoint, showed a nominally significant 15% reduction (HR 0.85; 95% CI 0.73-0.98) in the alirocumab group, driven largely by the high-baseline-LDL-C subgroup 15. This mortality signal, though hypothesis-generating, contributed to the regulatory rationale for expanded indications across all four jurisdictions discussed above.

Safety data were reassuring. Neurocognitive event rates did not differ between groups. Injection-site reactions occurred in 3.8% of alirocumab patients versus 2.1% on placebo. The trial used a blinded dose-adjustment algorithm: patients started on 75 mg every two weeks, with up-titration to 150 mg if LDL-C remained ≥50 mg/dL, and down-titration to placebo if LDL-C dropped below 15 mg/dL on two consecutive measurements. This design embedded safety monitoring for very low LDL-C directly into the protocol.

Regulatory Differences Across Jurisdictions: A Side-by-Side View

The four major markets agree on core indications but diverge on reimbursement and access pathways. All four regulators approved alirocumab for HeFH and ASCVD with inadequate LDL-C control on maximally tolerated therapy. None require genetic confirmation of FH for prescribing, though clinical diagnostic criteria (Simon Broome, Dutch Lipid Clinic Network) are referenced in practice guidelines 16.

The most restrictive access pathway is Canada's provincial formulary system, where prior authorization with specialist sign-off is standard. The UK's NICE system requires meeting explicit LDL-C thresholds and documented intolerance or inadequacy of oral therapies. The U.S. has no formal national formulary restriction, but commercial and Medicare Part D plans impose step therapy and prior authorization at the payer level. EU member states vary widely: Germany applies no additional access restriction beyond EMA labeling, while France's Haute Autorité de Santé initially assigned a low improvement-of-medical-benefit (ASMR) rating, limiting reimbursement scope until 2020 label updates.

Across all four markets, alirocumab is classified as prescription-only with no biosimilar competition as of May 2026. The first alirocumab biosimilar applications are anticipated in the 2027-2028 timeframe following patent expiry timelines, which could meaningfully alter access economics in every jurisdiction.

Ongoing Post-Marketing Surveillance and Label Evolution

Regulators in all four jurisdictions maintain active pharmacovigilance requirements for alirocumab. The FDA requires periodic safety update reports (PSURs). The EMA mandates periodic benefit-risk evaluations through the PSUR single assessment procedure 8. Health Canada and the MHRA have analogous post-market reporting obligations.

Key pharmacovigilance signals monitored include hypersensitivity reactions (reported at <1% in clinical trials), injection-site reactions, and the theoretical concern around sustained very low LDL-C concentrations. The EBBINGHAUS neurocognitive substudy of FOURIER (evaluating evolocumab, the other approved PCSK9 inhibitor) found no cognitive impairment at LDL-C levels as low as <25 mg/dL over a median 19 months, and ODYSSEY OUTCOMES corroborated this finding for alirocumab 17.

Current label updates under review include potential pediatric indications for HeFH in adolescents aged 8 to 17 years, based on phase III data from the ODYSSEY KIDS trial, with regulatory decisions expected in 2026-2027 across the FDA and EMA 18.

Alirocumab 300 mg monthly dosing received label inclusion across all four markets between 2019 and 2021, providing an alternative for patients who prefer fewer injections, with bioequivalent LDL-C reduction demonstrated versus 150 mg biweekly in the ODYSSEY CHOICE II study 19.